8th Annual HealthTech Investment Forum 2021 | Sachs Associates Ltd | 5 October 2021 | Virtual Event

Due to the pandemic we have decided that for the second time Sachs Basel events will be held in a digital format, thus allowing us to support our community and past attendees. We will provide both the usual stimulating programme and the networking opportunities through the online meeting system. We are constantly reviewing the situation and circumstances permitting, plan to announce in June that part of the Sachs Autumn Life Sciences Week programme will be delivered physically in Basel on the 7th and 8th of October. This would include live speeches and presentations as part of the 21st BEF with in person meetings and the event reception for both events. We will update all those who registered and when registering please indicate by ticking the appropriate box whether you would be interested in attending in person. Updates on any possible hybrid format will be posted on this website.​

The main programme for the 8th Annual HTIF is spread throughout 2 days (5th-6th of October) and will include HealthTech Innovation Day, focusing on Investment & Partnership in MedTech and Digital Health, and Managing Covid-19 Pandemic & Future Global Threats Day, which will include keynotes covering global supply chain and diagnostics. The two days will feature more than 12 hours of high-level speeches, panel discussions and spotlight showcases by leading industry corporates. In addition, there is a global company showcase of 25+ presentations by established public, private, emerging and seed companies, offering innovative solutions and are seeking investment and partnering opportunities. We anticipate 300+ delegates drawn from Digital Health, MedTech/Device companies, banks, investors and advisors.

2021 Speakers

CONFIRMED KEYNOTE SPEAKERS:

Eyal Zimlichman
Deputy Director General, CMO & CIO, Sheba Medical Center

​Sir Menelas N. Pangalos
Executive Vice-President, R&D BioPharmaceuticals, AstraZeneca

CONFIRMED SPEAKERS & CHAIRS INCLUDE:​

Alan Carr, Contractor
Tunnell Government Services

Aleks Engel
Partner, Novo Holdings A/S

Andrea Carfi
Head, Vice President, Infectious Disease Research, Moderna, Inc.

​Anne-Kathrin Witt
Global Head Digital BD&L, Novartis International AG

Antoine Pau
Senior Partner, Truffle Capital

Akshay Agarwal
Partner, Oliver Wyman INC.​

Bibhash Mukhopadhyay
Independent - BM

Cameron Durrant
Chairman & CEO, Humanigen, Inc.

Claudia Colciago
Investment Manager, Takeda Digital Ventures LP

Clive Dix
CEO, C4X Discovery Holdings PLC

Chris Guiffre
CFO & COO, Pear Therapeutics, Inc.

David Braun
Global Head of Connected Health & Devices Business Solutions, Merck

Diana Saraceni
Co-Founder & General Partner, Panakès Partners SGR SpA

​Erin Duffy
Chief of Research & Development, CARB-X

Eyal Aviram
CEO, Galil Ofek Innovation

Florian Schödel
Owner, Philimmune, LLC

Guy Spigelman
EMEA Lead, Healthcare & Life Sciences Startups, Amazon Web Services

Henry Skinner
CEO, AMR Action Fund GP

Henry Zubaida
Senior Associate, Gilde Healthcare Partners

Ian Crosbie
CEO, Sequana Medical NV

Ittai Harel
Managing Partner, Pitango Venture Capital

Jean Kramarz
Head of Health, AXA Assistance

Jeffrey Cohen
Managing Director, Equity Research, Healthcare & Medical Technologies, Ladenburg Thalmann & Co. Inc.

Jennifer McMahon
Principal, Seroba Life Sciences

Jim Harper
Co-Founder & COO, Sonde Health

Johan Van Hoof
Global Therapeutic Area Head of ID & Vaccines & Managing Director, Janssen Vaccines & Prevention B.V.

Jonathan Goldstein
Director, Global Tech Partnerships, Boston Scientific

Joseph Payne
President & CEO, Arcturus Therapeutics, Inc.

Karin Kleinhans
Managing Partner, LSP (Life Sciences Partners)

Klaus Stoeckemann
Co-Founder & Managing Partner, Peppermint VenturePartners GmbH

Kurt Höller
Director of Business Creation, EIT Health e.V.

Laurent Choppe
Managing Partner, Cukierman & Co. Life Sciences

Lionel Carnot
Partner, Earlybird Venture Capital

Lior Teitelbaum
CBO, FutuRx Ltd.

Lloyd Diamond
President & CEO, PIXIUM VISION SA

Marc Heim
BU Director Respiratory & Immunology, AstraZeneca

Mark Andrews
Managing Director, PharmaVentures Ltd.

Martin Bott
CFO, BioVersys AG

Martin Pfister
Principal, High-Tech Gründerfonds Management GmbH

Max Herrmann
Managing Director, Stifel Financial Corp.

Michael Dudley
President & CEO, Qpex Biopharma, Inc.

Mike Karim
CEO, Oxford Endovascular Ltd.

Nathalie Charland
Senior Director, Scientific & Medical Affairs, Medicago

​Nicholas Jackson
Head of Vaccine Programs and Technology for R&D, Coalition for Epidemic Preparedness Innovations (CEPI)

Ophir Shahaf
VP Business Development, eHealth Ventures LP

Patrik Sobocki
Investment Director, Industrifonden

Philip Gordts
Co-Founder, CoviCept Therapeutics, LLC​

Regina Hodits
Managing Partner, Wellington Partners

Richard Marsden
CEO, Synairgen Research Ltd.

Robin Shattock
Professor of Mucosal Infection & Immunity, Imperial College London

Ron Chiarello
Founder & CEO, Alveo Technologies

Roy Wiesner
Managing Director, aMoon Fund

Rupert Winckler
Head of EMEA Business Development, Olympus Europa SE & Co. KG

Sahil Kirpekar
Head of Business Development, Otsuka Pharmaceutical Co., Ltd.

Sander van Deventer
Operating Partner, Forbion

Thijs Cohen Tervaert
Junior Partner, INKEF Capital BV

Thomas Evans
CSO & Board Director, Vaccitech Ltd.

Thomas Shrader
Managing Director & Healthcare Analyst, BTIG, LLC

Timothy Herpin, VP, Business Development
Infectious Diseases & Vaccines, Johnson & Johnson Innovation | Janssen Business Development

Tony Meehan
Chief Business Officer, Venatorx Pharmaceuticals

​Torsten Mummenbrauer
CEO, ExeVir Bio BV

Ulrich Mühlner
Founder & Managing Director, GrowthCube Partners LLC

Vishal Gulati
Venture Capital Investor, Draper Esprit

Yves Nordmann
Co-Founder & CMO, docdok.health Ltd.

2021 Sponsors

SILVER SPONSOR:
• EIT HEALTH E.V.

CONTRIBUTING SPONSOR:
• PHARMAVENTURES LTD.

SUPPORTER:
• BIOTECHGATE
• FREEMIND GROUP
• INSTINCTIF PARTNERS
• MEDISTRAVA
• PLATTFORM LIFE SCIENCES
• SWISS BIOTECH ASSOCIATION
• TIBEREND STRATEGIC ADVISORS, INC.